Feed aggregator

Remdesivir can save more lives where ICUs are overwhelmed

World Pharma News - Tue, 07/07/2020 - 12:00
Amid news that the United States has bought up virtually the entire global supply of remdesivir, a new Boston University School of Public Health (BUSPH) study outlines how the drug could save lives in countries with less hospital capacity, such as South Africa, where COVID-19 is beginning to overwhelm intensive care units (ICUs).

GSK and Medicago announce collaboration to develop a novel adjuvanted COVID-19 candidate vaccine

World Pharma News - Tue, 07/07/2020 - 10:00
GSK and Medicago announced a collaboration to develop and evaluate a COVID-19 candidate vaccine combining Medicago's recombinant Coronavirus Virus-Like Particles (CoVLP) with GSK's pandemic adjuvant system. CoVLPs mimic the structure of the virus responsible for COVID-19 disease, allowing them to be recognised by the immune system.

Novavax Secures $1.6 Billion from U.S. Government for COVID-19 Vaccine Program

Biospace news - Tue, 07/07/2020 - 02:00
Novavax said the funding will allow the company to participate in Operation Warp Speed, the government’s program that has a goal of supporting the development of hundreds of millions of vaccine doses by 2021.

Vor Biopharma Snags $110 Million to Advance AML Treatment into the Clinic

Biospace news - Tue, 07/07/2020 - 02:00
Vor secured $110 million in a Series B financing round that will be used to advance the company’s lead stem cell-based oncology asset into clinical trials.

Regeneron Receives $450 Million BARDA Contract for COVID-19 Antibody Cocktail

Biospace news - Tue, 07/07/2020 - 02:00
This deal with BARDA and the DoD supports continuing the manufacturing in order for it to be immediately available in the U.S. if the clinical trials are successful.

GSK, Medicago Forge Agreement to Develop Novel Adjuvanted COVID-19 Vaccine

Biospace news - Tue, 07/07/2020 - 02:00
GlaxoSmithKline is providing its pandemic adjuvant technology to another company to bolster the chances of developing a vaccine against COVID-19.

MyoKardia: The Precision Cardiac Medicine Company with Diversity and Inclusion at its Heart

Biospace news - Tue, 07/07/2020 - 02:00
Putting your employees and company culture first keeps the focus on inclusion and innovation, giving the company an incredible competitive advantage.

Cellectis' CAR-T Trial for Multiple Myeloma on Clinical Hold After Patient Death

Biospace news - Tue, 07/07/2020 - 02:00
Cellectis, based in Paris and New York, announced that the U.S. Food and Drug Administration (FDA) had placed a clinical hold on its MELANI-01 trial.

IM Therapeutics Brings First Personalized, Oral Therapy for Insulin Regulation to Clinical Trials

Biospace news - Tue, 07/07/2020 - 02:00
IM Therapeutics is developing a personalized, orally available small molecule therapeutic for diabetes. This is a milestone for autoimmune diseases and may be the first time diabetes patients can be preselected for a therapeutic based on whether they carry a specific gene.

Unum Therapeutics Forges Ahead with Acquisition of Kiq LLC

Biospace news - Tue, 07/07/2020 - 02:00
Unum Therapeutics announced on Monday that it has successfully completed its acquisition of Kiq LLC, a privately held biotechnology company with a focus on the discovery and development of precision kinase inhibitors.

Using Epo against COVID-19

World Pharma News - Mon, 07/06/2020 - 10:00
Erythropoietin (Epo) is actually a medication for anaemia. According to researchers at the Max Planck Institute of Experimental Medicine in Göttingen, the doping agent Epo could also be effective against COVID-19. The growth factor could mitigate severe disease progression and protect patients from long-term neurological effects when the Sars-CoV-2 virus attacks the brain.

Merck initiates first clinical trial of TLR7 and 8 inhibitor as a potential treatment for severe symptoms of COVID-19 infection

World Pharma News - Fri, 07/03/2020 - 10:00
Merck, a leading science and technology company, announced the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug application (IND) for M5049 for the treatment of patients with Covid-19 pneumonia. Merck will initiate a Phase II randomized, controlled clinical study evaluating the safety and efficacy of M5049 in this patient population.

BioSpace Movers & Shakers, July 3

Biospace news - Fri, 07/03/2020 - 02:00
Biopharma and life sciences companies bolster their executive teams and board with these Movers & Shakers.

Research Roundup: Multiple Molecules that Can Shut Down COVID-19 and More

Biospace news - Fri, 07/03/2020 - 02:00
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

Novartis resolves legacy litigation matters, finalizing settlement of speaker program litigation with Government in the US

World Pharma News - Thu, 07/02/2020 - 12:00
Novartis has finalized its previously disclosed agreement with the US Attorney's Office for the Southern District of New York, the New York State Attorney General, and relator Oswald Bilotta resolving a civil suit challenging speaker programs and other promotional events conducted from 2002 through 2011 by Novartis Pharmaceuticals Corporation in the US.

Newer variant of COVID-19-causing virus dominates global infections

World Pharma News - Thu, 07/02/2020 - 10:00
Research out today in the journal Cell shows that a specific change in the SARS-CoV-2 coronavirus virus genome, previously associated with increased viral transmission and the spread of COVID-19, is more infectious in cell culture. The variant in question, D614G, makes a small but effective change in the virus's 'Spike' protein, which the virus uses to enter human cells.

Pfizer and BioNTech announce early positive data from an ongoing Phase 1/2 study of mRNA-based vaccine candidate against SARS-CoV-2

World Pharma News - Wed, 07/01/2020 - 12:00
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced preliminary data from the most advanced of four investigational vaccine candidates from their BNT162 mRNA-based vaccine program, Project Lightspeed, against SARS-CoV-2, the virus causing the current global pandemic. The BNT162 program is evaluating at least four experimental vaccines, each of which represents a unique combination of mRNA format and target antigen.

Researchers identify multiple molecules that shut down SARS-Cov-2 polymerase reaction

World Pharma News - Wed, 07/01/2020 - 10:00
SARS-CoV-2, the coronavirus causing the global COVID-19 pandemic, uses a protein called polymerase to replicate its genome inside infected human cells. Terminating the polymerase reaction will stop the growth of the coronavirus, leading to its eradication by the human host's immune system.

Pfizer and BioNTech’s COVID-19 Vaccine Shows Early Positive Data

Biospace news - Wed, 07/01/2020 - 02:00
Pfizer and BioNTech indicate that this data, along with preclinical data and additional data being generated, will be leveraged to choose a dose level and pick the best vaccine candidate out of the several being evaluated.

Day After Intercept's Setback, Akero’s EFX Shows Promise in NASH Trial

Biospace news - Wed, 07/01/2020 - 02:00
Of the 40 patients who responded who had end-of-treatment biopsies, 48% showed at least a one-stage improvement in fibrosis without worsening of NAFLD activity score and 28% demonstrated at least a two-stage improvement in fibrosis.